GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sonic Healthcare Ltd (ASX:SHL) » Definitions » Quality Rank

Sonic Healthcare (ASX:SHL) Quality Rank


View and export this data going back to 1987. Start your Free Trial

What is Sonic Healthcare Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Sonic Healthcare Quality Rank Related Terms

Thank you for viewing the detailed overview of Sonic Healthcare's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonic Healthcare (ASX:SHL) Business Description

Traded in Other Exchanges
Address
225 George Street, Level 22, Grosvenor Place, Sydney, NSW, AUS, 2000
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the U.K., the second largest in Belgium and New Zealand and the third largest in the U.S. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the U.S. and 35% in Europe.